These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2422490)

  • 21. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
    Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
    Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.
    Biollaz J; Brunner HR; Gavras I; Waeber B; Gavras H
    J Cardiovasc Pharmacol; 1982; 4(6):966-72. PubMed ID: 6185790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood pressure response to angiotensin converting enzyme inhibitor in essential hypertension: its relation to the renin status and natriuresis during acute sodium loading.
    Hou CH; Chen YM; Wu KD; Hsieh BS
    J Formos Med Assoc; 1993 Nov; 92(11):942-7. PubMed ID: 7910063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced activity of the kallikrein-kinin system predominates over renin-angiotensin system overactivity in all conditions of sodium balance in essential hypertensives and family-related hypertension.
    Sànchez R; Nolly H; Giannone C; Baglivo HP; Ramírez AJ
    J Hypertens; 2003 Feb; 21(2):411-7. PubMed ID: 12569273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The persistent effect of long-term enalapril on pressure natriuresis in spontaneously hypertensive rats.
    Dukacz SA; Adams MA; Kline RL
    Am J Physiol; 1997 Jul; 273(1 Pt 2):F104-12. PubMed ID: 9249597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind comparison of captopril and enalapril in mild to moderate hypertension.
    Vlasses PH; Conner DP; Rotmensch HH; Fruncillo RJ; Danzeisen JR; Shepley KJ; Ferguson RK
    J Am Coll Cardiol; 1986 Mar; 7(3):651-60. PubMed ID: 3005384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of enalapril on renin, angiotensin converting enzyme activity, aldosterone and prostaglandins in patients with hypertension.
    Larochelle P; Gutkowska J; Schiffrin E; Kuchel O; Hamet P; Genest J
    Clin Invest Med; 1985; 8(3):197-201. PubMed ID: 2994932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of action and short-term hormonal responses to enalapril (MK 421) in normal subjects.
    Given BD; Taylor T; Hollenberg NK; Williams GH
    J Cardiovasc Pharmacol; 1984; 6(3):436-41. PubMed ID: 6202969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enalapril in essential hypertension.
    Herrera-Acosta J; Pérez-Grovas H; Fernández M; Arriaga J
    Drugs; 1985; 30 Suppl 1():35-46. PubMed ID: 2994986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of enalapril (MK-421), an orally active angiotensin I converting enzyme inhibitor, on blood pressure, active and inactive plasma renin, urinary prostaglandin E2, and kallikrein excretion in conscious rats.
    Schiffrin EL; Gutkowska J; Thibault G; Genest J
    Can J Physiol Pharmacol; 1984 Jan; 62(1):116-23. PubMed ID: 6143602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure.
    Sweet CS; Gaul SL; Reitz PM; Blaine EH; Ribeiro LT
    J Hypertens Suppl; 1983 Oct; 1(1):53-63. PubMed ID: 6100609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.
    Marney A; Kunchakarra S; Byrne L; Brown NJ
    Hypertension; 2010 Oct; 56(4):728-33. PubMed ID: 20679179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I.
    Inglessis N; Nussberger J; Hagmann M; Hiesse-Provost O; Insuasty J; Reid J; Ménard J; Brunner HR
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):986-93. PubMed ID: 7564346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of enalapril (MK421), an angiotensin converting enzyme inhibitor, on the conscious pregnant ewe and her foetus.
    Broughton Pipkin F; Wallace CP
    Br J Pharmacol; 1986 Mar; 87(3):533-42. PubMed ID: 3026539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial.
    Baba T; Murabayashi S; Takebe K
    Diabetologia; 1989 Jan; 32(1):40-4. PubMed ID: 2540054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced pressor responsiveness to norepinephrine in type II diabetes. Effect of ACE inhibition.
    Ciavarella A; Mustacchio A; Ricci C; Capelli M; Vannini P
    Diabetes Care; 1994 Dec; 17(12):1484-7. PubMed ID: 7882823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.
    Lewis RA; Baker KM; Ayers CR; Weaver BA; Lehman MR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S12-5. PubMed ID: 2580164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enalapril versus combined enalapril and nadolol treatment: effects on blood pressure, heart rate, humoral variables, and plasma potassium at rest and during exercise in hypertensive patients.
    Sullivan PA; Daly B; O'Connor R
    Cardiovasc Drugs Ther; 1992 Jun; 6(3):261-5. PubMed ID: 1637731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension.
    Schwartz JB; Taylor A; Abernethy D; O'Meara M; Farmer J; Young J; Nelson E; Pool J; Mitchell JR
    J Cardiovasc Pharmacol; 1985; 7(4):767-76. PubMed ID: 2410720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421".
    Gavras H; Biollaz J; Waeber B; Brunner HR; Gavras I; Davies RO
    Lancet; 1981 Sep; 2(8246):543-7. PubMed ID: 6116000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.